Literature DB >> 33922105

Fast-Onset Diffuse Interstitial Lung Disease in Anti-MDA5 Antibodies-Associated Amyopathic Dermatomyositis.

Houari Aissaoui1, Kinan Drak Alsibai2,3, Naji Khayath4.   

Abstract

Anti-MDA5 antibodies-associated amyopathic dermatomyositisis a rare autoimmune disease that involve polyarthritis, cutaneous and pulmonary manifestations. The development of rapidly progressing interstitial lung disease is a life-threatening complication. We report the case of a 45-year-old woman without medical history, who was addressed to the Pulmonary Department for a polyarthritis with dry cough and hypoxemic dyspnea. Initially there was neither cutaneous manifestation nor interstitial lung disease on chest CT scan. After a few days, the patient developed fatal acute respiratory failure with diffuse ground glass opacities. Identification of anti-MDA5 antibodies allowed establishing diagnosis, despite the fact that the first immunological assessment was negative. Corticosteroid bolus of 1 g for three days and immunosuppressive treatment by cyclophosphamide was only initiated at the acute respiratory distress syndrome stage. Given the rapidly unfavorable prognosis of this entity of amyopathic dermatomyositis, the testing for anti-MDA5 antibodies should be recommended in case of progressive pulmonary symptoms associated with joint signs in order to identify this disease at an early stage and to begin rapid and adequate management.

Entities:  

Keywords:  anti-MDA5 antibodies; dermatomyositis; polyarthritis; rapidly progressive interstitial pneumopathy

Year:  2021        PMID: 33922105     DOI: 10.3390/clinpract11020035

Source DB:  PubMed          Journal:  Clin Pract        ISSN: 2039-7275


  20 in total

1.  Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.

Authors:  Koichi Yamaguchi; Aya Yamaguchi; Chiharu Kashiwagi; Yuri Sawada; Kohei Taguchi; Kazue Umetsu; Kazuma Oshima; Megumi Uchida; Masafumi Suzuki; Shunichi Kono; Masao Takemura; Hiroaki Masubuchi; Shinsuke Kitahara; Kenichiro Hara; Toshitaka Maeno; Sei-Ichiro Motegi; Yoshinao Muro; Toru Sakairi; Takeshi Hisada; Masahiko Kurabayashi
Journal:  Respir Med       Date:  2018-05-22       Impact factor: 3.415

2.  Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists.

Authors:  Hitoshi Kohsaka; Tsuneyo Mimori; Takashi Kanda; Jun Shimizu; Yoshihide Sunada; Manabu Fujimoto; Yasushi Kawaguchi; Masatoshi Jinnin; Yoshinao Muro; Shoichiro Ishihara; Hiroyuki Tomimitsu; Akiko Ohta; Takayuki Sumida
Journal:  J Dermatol       Date:  2018-12-18       Impact factor: 4.005

3.  [Four cases of interstitial pneumonia associated with amyopathic dermatomyositis characterized by the anti-CADM-140 antibody].

Authors:  Kazuma Nagata; Keisuke Tomii; Shigeki Nanjo; Mio Kubota; Ryo Tachikawa; Mari Nishio
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2011-01

4.  Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody.

Authors:  Hua Cao; Meng Pan; Yanqing Kang; Qunli Xia; Xia Li; Xiaoqing Zhao; Ruofei Shi; Jianghua Lou; Min Zhou; Masataka Kuwana; Xiaoyi Ding; Jie Zheng
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Kei Hoshino; Masashi Akiyama
Journal:  Rheumatology (Oxford)       Date:  2011-12-30       Impact factor: 7.580

Review 6.  Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features.

Authors:  Drew J B Kurtzman; Ruth Ann Vleugels
Journal:  J Am Acad Dermatol       Date:  2017-12-09       Impact factor: 11.527

7.  Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology.

Authors:  Cord Sunderkötter; Alexander Nast; Margitta Worm; Reinhard Dengler; Thomas Dörner; Horst Ganter; Reinhard Hohlfeld; Arthur Melms; Nico Melzer; Kai Rösler; Jens Schmidt; Michael Sinnreich; Maggi C Walter; Julia Wanschitz; Heinz Wiendl
Journal:  J Dtsch Dermatol Ges       Date:  2016-03       Impact factor: 5.584

8.  Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations.

Authors:  Ho So; Ricky W-K Ip; Victor T-L Wong; Ronald M-L Yip
Journal:  Int J Rheum Dis       Date:  2018-01-30       Impact factor: 2.454

9.  Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Kei Hoshino; Masashi Akiyama; Koji Tamakoshi
Journal:  Arthritis Res Ther       Date:  2011-12-22       Impact factor: 5.156

10.  Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?

Authors:  Satoshi Ikeda; Machiko Arita; Mitsunori Morita; Satoshi Ikeo; Akihiro Ito; Fumiaki Tokioka; Maki Noyama; Kenta Misaki; Kenji Notohara; Tadashi Ishida
Journal:  BMC Pulm Med       Date:  2015-12-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.